The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers
Open Access
- 1 June 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Neglected Tropical Diseases
- Vol. 14 (6), e0008259
- https://doi.org/10.1371/journal.pntd.0008259
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015—A Retrospective Observational StudyThe Journal of Infectious Diseases, 2019
- QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patientPLoS Neglected Tropical Diseases, 2017
- Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targetedPLoS Neglected Tropical Diseases, 2017
- A Randomized, Controlled Trial of ZMapp for Ebola Virus InfectionThe New England Journal of Medicine, 2016
- Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT ProlongationJournal of the American College of Cardiology, 2016
- Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 DaysClinical Infectious Diseases, 2016
- Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in GuineaPLoS Medicine, 2016
- Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adultsInternational journal of clinical pharmacology and therapeutics, 2015
- Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG.2001
- Interactions of a Series of Fluoroquinolone Antibacterial Drugs with the Human Cardiac K+Channel HERGMolecular Pharmacology, 2001